过去一年中添加的文章，按日期排序
Antagonism of epidermal growth factor receptor signaling favors hepatitis E virus life cycle
K Woytinek, M Glitscher, E Hildt - Journal of Virology, 2024 - Am Soc Microbiol
11 天前 - … the well-known EGFR inhibitor erlotinib to explore potential effects on key steps of
the viral life cycle. As previously demonstrated in other studies, erlotinib caused a significant …
the viral life cycle. As previously demonstrated in other studies, erlotinib caused a significant …
Phase I–IV Drug Trials on Hepatocellular Carcinoma in an Asian Population: A Systematic Review of Ten Years Studies
A Raghav, GB Jeong - 2024 - preprints.org
11 天前 - … for patients with HCC. Methods: This systematic review included phase I, II, III, and
IV … , randomized, double-blind, placebocontrolled trial of sorafenib plus erlotinib in patients …
IV … , randomized, double-blind, placebocontrolled trial of sorafenib plus erlotinib in patients …
A phase III randomized, open-label study to establish the superiority of triple oral metronomic therapy (OMCT) used in addition to chemotherapy regimen (paclitaxel+ …
16 天前 - … Conclusions: This study demonstrates that the addition of triple OMCT to paclitaxel
and carboplatin chemotherapy is an effective and safe treatment option for patients with …
and carboplatin chemotherapy is an effective and safe treatment option for patients with …
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
S Zhou, N Kishi, P Alerasool, NC Rohs - Targeted Oncology, 2024 - Springer
20 天前 - … Ultimately, 34 phase III RCTs comprising 15,887 patients were included in this
meta-… The risk of high-grade rash was significantly increased in patients treated with erlotinib or …
meta-… The risk of high-grade rash was significantly increased in patients treated with erlotinib or …
Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series
M Mehdi, A Szabo, A Shreenivas… - Therapeutic …, 2024 - journals.sagepub.com
32 天前 - … patients were treated with matched targeted therapy, with three having durable
benefit: (i) erlotinib … fusion (fifth line); and (iii) dabrafenib/trametinib for BRAF N486_P490del (…
benefit: (i) erlotinib … fusion (fifth line); and (iii) dabrafenib/trametinib for BRAF N486_P490del (…
Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer
37 天前 - … patients with EDP induced by EGFRi from 2017 to 2023 and included sixteen patients
in our study. … patients (57%) received erlotinib and one patient (6%) received afatinib. Six …
in our study. … patients (57%) received erlotinib and one patient (6%) received afatinib. Six …
CLO24-092: Neoadjuvant Tyrosine Kinase Inhibitors (TKIs) Efficacy in EGFR Positive Stage III Non–Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta …
JK Lalusis, JL Padayao - Journal of the National Comprehensive Cancer …, 2024 - jnccn.org
77 天前 - … were included in the meta-analysis with a cumulative total of 357 patients. It was
found that these studies have a common TKI in use—erlotinib. The quality of the studies were …
found that these studies have a common TKI in use—erlotinib. The quality of the studies were …
[HTML][HTML] … of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study …
L Weiss, LE Fischer, V Heinemann, F Gieseler… - ESMO open, 2024 - Elsevier
95 天前 - … patients with metastatic disease. Three trials had a phase II design, whereas two
studies were phase III … -in treatment with gemcitabine/erlotinib and subsequently transitioned to …
studies were phase III … -in treatment with gemcitabine/erlotinib and subsequently transitioned to …
Exploring the role of oral maintenance chemotherapy in locally advanced oral cavity squamous cell cancers-A phase II randomized controlled trial.
P Kaul, PK Garg - European Journal of Surgical Oncology, 2024 - ejso.com
142 天前 - … , celecoxib, and erlotinib has been approved for locally … III/IV resectable oral cavity
SCCs post curative treatment with radical surgery followed by adjuvant RT or CRT. Patients …
SCCs post curative treatment with radical surgery followed by adjuvant RT or CRT. Patients …
[HTML][HTML] The great need to overcome osimertinib resistance in advanced nonsmall cell lung cancer: from combination strategies to fourthgeneration tyrosine kinase …
G Bronte, A Belloni, L Calabrò, L Crinò - Frontiers in Oncology, 2024 - frontiersin.org
178 天前 - … Many randomized phase III trials showed, in patients with advanced NSCLC and
common EGFR mutations, the superiority of EGFR TKIs, ie gefitinib, erlotinib, afatinib, in the …
common EGFR mutations, the superiority of EGFR TKIs, ie gefitinib, erlotinib, afatinib, in the …